Skip Navigation LinksHome > December 2009 - Volume 9 - Issue 6 > Evidence of adherence to allergen-specific immunotherapy
Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e328332b8df
Immunotherapy: Edited by Giovanni Passalacqua and Robert Bush

Evidence of adherence to allergen-specific immunotherapy

Senna, Gianenrico; Ridolo, Erminia; Calderon, Moises; Lombardi, Carlo; Canonica, Giorgio W; Passalacqua, Giovanni

Collapse Box


Purpose of review: The main feature of allergen-specific immunotherapy is its capacity to modify the natural history of the disease, reducing the development of asthma and new sensitizations after 3–4 years of treatment. For this reason, adherence to the therapy is mandatory, as happens for all chronic medical treatment.

Recent findings: Though subcutaneous immunotherapy is administered directly by physicians, the rate of adherence is surprisingly low, at less than 70%. The explanations for a poor subcutaneous immunotherapy adherence include inconvenience, lack of efficacy, costs and loss of working hours.

Local nasal immunotherapy has a very low adherence rate (27%), due to the local nasal side effects.

For sublingual immunotherapy, data are available from clinical trials and postmarketing surveys, which are favourable overall (rates of compliance >75%). Cost was the most common reason for discontinuation, followed by inconvenience, feeling of inefficacy and side effects.

Summary: Studies addressing the adherence to allergen-specific immunotherapy in literature are lacking. In real life, costs and patient education are crucial issues in conditioning adherence to this treatment. Reduction of costs and more efforts in education of patients and also specialists may improve the adherence to immunotherapy.

Copyright © 2009 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.